Home Hemispherx BioPharma Hemispherx News Hemispherx Biopharma (NYSE:HEB) Initiated at Maxim with Buy and $8 Target

Hemispherx Biopharma (NYSE:HEB) Initiated at Maxim with Buy and $8 Target

15
0

Maxim analyst Jason McCarthy initiated Hemispherx with a Buy rating and a price target of $8, citing the company’s “differentiated immune oncology approach”.

Ampligen leverages the innate immune response to alter the chemokine profile in the tumor microenvironment. The analyst notes that multiple early stage combination studies are “ongoing”, but as the immune oncology space grows, he sees “combinations” as the likely key that will unlock “larger market opportunities.” McCarthy believes that Ampligen offers upside with data updates expected over 2019 and 2020.

Click on the link below to read the full report.

Maxim Research Report – Hemispherx Biopharma, Inc. (NYSE:HEB)

LEAVE A REPLY

Please enter your comment!
Please enter your name here